Evaluation of three commercial screening tests for AIDS virus antibodies

J. R. Carlson, Steven Heye Hinrichs, J. Yee, M. B. Gardner, N. C. Pedersen

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Three commercial enzyme-linked immunosorbent assays (ELISA) for acquired immune deficiency syndrome (AIDS) virus antibodies were evaluated using serum that had been characterized by an ELISA and western blot procedure developed at the University of California at Davis (UCD). Each of the commercial tests was more specific than the UCD ELISA, but the UCD ELISA was more sensitive in the detection of sera that lacked reactivity by western blot to the envelope glycoprotein (gp-41). The HTLV-III Bio-EnzaBead® (Litton Bionetics, Charleston, SC) was less sensitive and specific than the Abbott® HTLV-III EIA (Abbott Laboratories, North Chicago, IL) or the Virgo® HTLV-III ELISA (Electro-Nucleonics Inc., Columbia, MD). Overall, 22.9% (57 of 250) and 51.0% of sera that were repeatedly (x2) positive by commercial screening kits tested at blood donor centers and clinical laboratories, respectively, were confirmed by western blot. These results indicate that the screening assays for AIDS virus antibodies are not equal in performance and that positive screening test results must be confirmed by a more specific test like western blot before results are released.

Original languageEnglish (US)
Pages (from-to)357-359
Number of pages3
JournalAmerican journal of clinical pathology
Volume86
Issue number3
DOIs
StatePublished - Jan 1 1986

Fingerprint

Enzyme-Linked Immunosorbent Assay
HIV
Western Blotting
Antibodies
Serum
Blood Donors

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Evaluation of three commercial screening tests for AIDS virus antibodies. / Carlson, J. R.; Hinrichs, Steven Heye; Yee, J.; Gardner, M. B.; Pedersen, N. C.

In: American journal of clinical pathology, Vol. 86, No. 3, 01.01.1986, p. 357-359.

Research output: Contribution to journalArticle

Carlson, J. R. ; Hinrichs, Steven Heye ; Yee, J. ; Gardner, M. B. ; Pedersen, N. C. / Evaluation of three commercial screening tests for AIDS virus antibodies. In: American journal of clinical pathology. 1986 ; Vol. 86, No. 3. pp. 357-359.
@article{ca0574d9712141b3b8eb7035a66f2f4d,
title = "Evaluation of three commercial screening tests for AIDS virus antibodies",
abstract = "Three commercial enzyme-linked immunosorbent assays (ELISA) for acquired immune deficiency syndrome (AIDS) virus antibodies were evaluated using serum that had been characterized by an ELISA and western blot procedure developed at the University of California at Davis (UCD). Each of the commercial tests was more specific than the UCD ELISA, but the UCD ELISA was more sensitive in the detection of sera that lacked reactivity by western blot to the envelope glycoprotein (gp-41). The HTLV-III Bio-EnzaBead{\circledR} (Litton Bionetics, Charleston, SC) was less sensitive and specific than the Abbott{\circledR} HTLV-III EIA (Abbott Laboratories, North Chicago, IL) or the Virgo{\circledR} HTLV-III ELISA (Electro-Nucleonics Inc., Columbia, MD). Overall, 22.9{\%} (57 of 250) and 51.0{\%} of sera that were repeatedly (x2) positive by commercial screening kits tested at blood donor centers and clinical laboratories, respectively, were confirmed by western blot. These results indicate that the screening assays for AIDS virus antibodies are not equal in performance and that positive screening test results must be confirmed by a more specific test like western blot before results are released.",
author = "Carlson, {J. R.} and Hinrichs, {Steven Heye} and J. Yee and Gardner, {M. B.} and Pedersen, {N. C.}",
year = "1986",
month = "1",
day = "1",
doi = "10.1093/ajcp/86.3.357",
language = "English (US)",
volume = "86",
pages = "357--359",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "3",

}

TY - JOUR

T1 - Evaluation of three commercial screening tests for AIDS virus antibodies

AU - Carlson, J. R.

AU - Hinrichs, Steven Heye

AU - Yee, J.

AU - Gardner, M. B.

AU - Pedersen, N. C.

PY - 1986/1/1

Y1 - 1986/1/1

N2 - Three commercial enzyme-linked immunosorbent assays (ELISA) for acquired immune deficiency syndrome (AIDS) virus antibodies were evaluated using serum that had been characterized by an ELISA and western blot procedure developed at the University of California at Davis (UCD). Each of the commercial tests was more specific than the UCD ELISA, but the UCD ELISA was more sensitive in the detection of sera that lacked reactivity by western blot to the envelope glycoprotein (gp-41). The HTLV-III Bio-EnzaBead® (Litton Bionetics, Charleston, SC) was less sensitive and specific than the Abbott® HTLV-III EIA (Abbott Laboratories, North Chicago, IL) or the Virgo® HTLV-III ELISA (Electro-Nucleonics Inc., Columbia, MD). Overall, 22.9% (57 of 250) and 51.0% of sera that were repeatedly (x2) positive by commercial screening kits tested at blood donor centers and clinical laboratories, respectively, were confirmed by western blot. These results indicate that the screening assays for AIDS virus antibodies are not equal in performance and that positive screening test results must be confirmed by a more specific test like western blot before results are released.

AB - Three commercial enzyme-linked immunosorbent assays (ELISA) for acquired immune deficiency syndrome (AIDS) virus antibodies were evaluated using serum that had been characterized by an ELISA and western blot procedure developed at the University of California at Davis (UCD). Each of the commercial tests was more specific than the UCD ELISA, but the UCD ELISA was more sensitive in the detection of sera that lacked reactivity by western blot to the envelope glycoprotein (gp-41). The HTLV-III Bio-EnzaBead® (Litton Bionetics, Charleston, SC) was less sensitive and specific than the Abbott® HTLV-III EIA (Abbott Laboratories, North Chicago, IL) or the Virgo® HTLV-III ELISA (Electro-Nucleonics Inc., Columbia, MD). Overall, 22.9% (57 of 250) and 51.0% of sera that were repeatedly (x2) positive by commercial screening kits tested at blood donor centers and clinical laboratories, respectively, were confirmed by western blot. These results indicate that the screening assays for AIDS virus antibodies are not equal in performance and that positive screening test results must be confirmed by a more specific test like western blot before results are released.

UR - http://www.scopus.com/inward/record.url?scp=0022477235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022477235&partnerID=8YFLogxK

U2 - 10.1093/ajcp/86.3.357

DO - 10.1093/ajcp/86.3.357

M3 - Article

VL - 86

SP - 357

EP - 359

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 3

ER -